retatrutide phase 2 trial type 2 diabetes weight loss 2024 with as compared to licenced obesity Retatrutide: A Triple Agonist Shaping

Vella is supported by DK78646 and by DK82396

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

Unfortunately, many individuals are using GLP-1 inhibitors to facilitate weight loss when it isnt medically necessary, exposing them to potential side effects without clear benefits

Zhong, J

That's why her approach to healthy weight loss involves more than medication

Table: Comparing the Major GLP-1 Receptor Agonist Drugs To summarize the key characteristics of the GLP-1 drugs up to this point (prior to semaglutide), the table below compares their properties: Table 2: Comparison of GLP-1based therapies